

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**LEUPRORELIN EXTENDED-RELEASE INJECTION (SYH9016)
OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Leuporelin Extended-release Injection (SYH9016) (the “**Product**”), a GnRH receptor agonist developed by the Group, has obtained approval granted by the National Medical Products Administration (NMPA) of the People’s Republic of China to conduct clinical trials in China.

The Product is the first modified leuporelin product obtaining clinical trial approval in China. Utilising the Group’s long-acting delivery technology platform and excipient with good biocompatibility, the Product is injected subcutaneously to form a gel depot that enables long-acting drug delivery. The Product is administered once a month. Compared with the leuporelin microsphere products on the market, the Product does not require complicated preparation prior to administration, and delivers a smaller dosing volume with its thinner injection needle, which is expected to reduce pain at the injection site and improve ease of use and patient compliance. Preclinical studies demonstrated that the Product had favourable safety and efficacy profiles.

The indication for this clinical trial approval is solid tumors. In addition, the Product can also be used for the treatment of endometriosis, central precocious puberty, etc., providing a promising clinical development value. This clinical trial approval is the first significant achievement of the Group’s development in the field of long-acting GnRH agonists, which lays a solid foundation for the development of other GnRH agonist products.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 30 December 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.